Namenda
In brief
- In our pharmacy, you can buy namenda without a prescription, with delivery in 5–14 days throughout Australia. Discreet and anonymous packaging.
- Namenda (memantine) is used to treat moderate to severe Alzheimer’s disease; it is an N‑methyl‑D‑aspartate (NMDA) receptor antagonist that modulates glutamatergic activity to reduce excitotoxic neuronal damage.
- The usual dose for adults is to start at 5 mg once daily and increase by 5 mg weekly to a maintenance dose of 10 mg twice daily (20 mg/day total); Namenda XR is started at 7 mg once daily and titrated weekly to a maximum of 28 mg once daily. Dose reductions are recommended in severe renal impairment.
- Administered orally as tablets (commonly 10 mg), oral solution (10 mg/mL) or extended‑release capsules (7, 14, 21, 28 mg for XR formulations).
- Some patients may notice changes within 1–4 weeks, but symptomatic benefit can take several weeks to become apparent.
- Therapeutic effects are maintained with daily dosing; memantine has a long elimination half‑life (around 60–80 hours), so once‑ or twice‑daily dosing sustains effect while treatment continues.
- Avoid excessive alcohol — alcohol can worsen dizziness, confusion and other CNS side effects; it is advisable not to consume alcohol while taking memantine.
- The most common side effect is dizziness.
- Would you like to try namenda without a prescription?
Basic Namenda Information
- INN (International Nonproprietary Name): Memantine
- Brand Names Available In Australia: Ebixa, GenRx Memantine (tablets 10 mg); main suppliers listed include Lundbeck and GenRx.
- ATC Code: N06DX01
- Forms & Dosages: Tablets commonly available as 5 mg and 10 mg strengths, with 10 mg tablets most common.
- Manufacturers In Australia: Lundbeck; GenRx (generics).
- Registration Status In Australia: Listed brands and suppliers are present for the Australian market; local regulatory registration details not specified in the raw dataset beyond brand listings.
- OTC / Rx Classification: Prescription only
Neueste Research Findings
What Does Recent European Research Say About Memantine?
Recent Austrian and EU analyses from 2022–2025 converge on a consistent but modest signal for memantine in Alzheimer’s disease.
These analyses indicate symptomatic benefit in moderate–severe Alzheimer’s disease with stabilisation or improvement in activities of daily living and some cognitive measures compared with placebo.
Benefits in mild Alzheimer’s disease remain inconsistent across studies and meta-analyses.
National registries and multicentre observational cohorts in Austria and neighbouring EU states show memantine frequently used alongside acetylcholinesterase inhibitors for later‑stage disease.
Safety signals remain unchanged from earlier clinical trials, with dizziness, constipation and confusion the most commonly reported adverse effects.
Serious adverse events are rare in the datasets reviewed between 2022 and 2025.
Meta-analyses covering 2018–2024 that incorporated newer EU data report small‑to‑moderate effect sizes on global clinical impression and ADL scales in moderate–severe disease.
Heterogeneity across studies mainly reflects differences in study duration and the outcome instruments used for cognition and function.
How Clinicians Should Read These Findings
The overall evidence supports memantine as a symptomatic option for moderate–severe Alzheimer’s disease rather than a disease‑modifying therapy.
Population‑level data from Austria support real‑world use alongside AChE inhibitors in later stages, and tolerability aligns with the trial literature.
Summary Table: Austrian Cohorts Versus Broader EU Cohorts
| Dataset | Use Pattern | Effect Size (Clinical) | Common Safety Signals |
|---|---|---|---|
| Austrian Registries / Specialist Clinics (2022–2025) | Primarily for moderate–severe AD; frequent combination with AChE inhibitors | Modest stabilisation of ADL over 6–12 months; small cognitive benefit in some measures | Dizziness, constipation, confusion; serious events rare |
| EU Multicentre Observational Cohorts & Meta‑Analyses | Moderate–severe AD use common; heterogenous study designs | Small‑to‑moderate effects on global clinical impression and ADL | Same profile: dizziness, constipation, confusion; low rates of serious adverse events |
Clinical Effectiveness In Austria
Who Sees Benefit In Real Practice?
Austrian e‑prescription and Sozialversicherung data show memantine is principally prescribed for patients with moderate–severe Alzheimer’s disease following specialist assessment or geriatric review.
Initiations are commonly recorded from specialist outpatient clinics or geriatric units after a clear functional decline is documented.
Real‑world matched cohort studies in Austria describe slower deterioration in ADL scores over 6–12 months among memantine‑treated patients compared with controls.
Causality is limited by observational design, but these findings align with clinical trial data showing functional benefit in later stages of disease.
Tolerability In Austrian Patients
Adverse events most often prompting dose review are dizziness and constipation, with most patients able to continue therapy after a dose adjustment or simple supportive measures.
Severe adverse events remain uncommon in Austrian practice.
Prescribing Patterns And Care Pathways
Memantine is frequently added to ongoing acetylcholinesterase inhibitor therapy rather than replacing it in cases of progression to moderate disease.
Pharmacies and prescribers are expected to document memantine on E‑Medikation via the e‑card to ensure continuity and to help identify interactions.
Local Dosing Practise
Typical initiation in Austria follows the titration schedule starting at 5 mg once daily and increasing weekly to a maintenance dose of 10 mg twice daily (20 mg/day).
Recommendation For Clinicians
Consider starting memantine when functional decline is apparent despite best supportive care or when specialist review indicates moderate–severe disease.
Monitor patients clinically and document therapy on the e‑card to support reconciliation at pharmacies and primary care.
| Setting | Prescribing Rate | Combination With AChE Inhibitors | Monitored Outcomes |
|---|---|---|---|
| Specialist Clinics / Geriatrics | Higher | Very Common | ADL, cognition, institutionalisation risk |
| General Practice | Lower | Moderate | ADL, tolerability review |
Indications And Off‑Label Uses
What Is Memantine Approved For?
Per EMA guidance and Austrian practice, memantine is approved for symptomatic treatment of moderate to severe Alzheimer’s disease.
Standard adult dosing is titrated from 5 mg/day to a maintenance of 20 mg/day given as 10 mg twice daily.
Extended‑release formulations are licensed in North America but are not commonly used in Austria.
Off‑Label Uses Observed In Practice
Some specialist teams use memantine as adjunctive therapy in mixed dementia syndromes or when a vascular contribution is suspected, but evidence for these uses is sparse and mainly observational.
Paediatric Use
Use in children is not approved and safety and efficacy are unestablished.
Decision Points For Treatment Initiation
- Approved Indication: Moderate–severe Alzheimer’s disease (symptomatic therapy).
- Potential Off‑Label Scenarios: Selected mixed dementia or vascular contribution under specialist supervision.
- Treatment Duration: Typically long‑term with periodic review; consider discontinuation if no functional benefit after an adequate trial.
Composition And Brands In Austria
What Is In The Tablet?
The active ingredient is memantine (INN), usually provided as memantine hydrochloride in tablet or oral solution formulations.
Common Austrian Brands And Forms
Ebixa and Memantin Genericon are commonly available in Austria as 10 mg tablets and as a 10 mg/mL oral solution in standard pack sizes.
Typical Packaging
Tablets are sold in blister packs of 28, 30, 56 or 98 units, and oral solution is typically supplied in 30 mL or 50 mL bottles with a dosing syringe.
XR Formulations
Extended‑release capsules such as Namenda XR are listed in North America but are not commonly used in the Austrian market.
Pharmacist Checklist
- Check excipient lists for allergy considerations.
- Reconcile generic substitutions on E‑Medikation with prescriber intent.
Contraindications And Precautions
Who Should Not Take Memantine?
Absolute contraindication is a known hypersensitivity to memantine or any excipient in the product.
Relative Contraindications And Cautions
Exercise caution and monitor in patients with severe renal impairment, a history of seizures, conditions that cause urine alkalinisation, and unstable cardiovascular disease.
Severe renal impairment with creatinine clearance 5–29 mL/min requires a reduced maximum dose, typically 5 mg twice daily.
Hepatic impairment generally requires monitoring rather than routine dose reduction for mild–moderate disease.
Activities To Avoid Or Monitor
Newly initiated patients should be warned about dizziness and balance impairment and advised to avoid driving or working at height until stability is confirmed.
Monitoring Checklist For Pharmacists And Clinicians
- Confirm absence of allergy to memantine and excipients.
- Review renal function and adjust dose if CrCl is severely reduced.
- Assess fall risk and review concomitant medications that raise urine pH.
Dosing Guidelines
How Should Memantine Be Started And Adjusted?
Standard adult dosing in Austria starts at 5 mg once daily and increases by 5 mg weekly to a maintenance of 10 mg twice daily (total 20 mg/day).
When Switching From An XR Formulation
Confirm the equivalent total daily dose if switching from an extended‑release product, though XR use is rare in Austria.
Renal Dosing
For severe renal impairment (CrCl 5–29 mL/min) reduce the typical maintenance dose to 5 mg twice daily unless nephrology advice suggests otherwise.
Administration Notes
Tablets should be swallowed whole.
Use the supplied dosing syringe for the 10 mg/mL oral solution when patients have swallowing difficulties.
Missed Dose Advice
If a dose is missed, take it when remembered unless it is close to the next dose and do not double the next dose.
| Scenario | Recommended Action |
|---|---|
| Start | 5 mg once daily, increase by 5 mg weekly |
| Maintenance | 10 mg twice daily (20 mg/day) |
| Severe Renal Impairment (CrCl 5–29 mL/min) | 5 mg twice daily |
Overview Of Interactions
What Interacts With Memantine?
Memantine has few classic pharmacokinetic interactions, but renal clearance is sensitive to urine pH, so alkalinising agents may reduce elimination.
Avoid or monitor co‑prescription with carbonic anhydrase inhibitors and sodium bicarbonate which can raise urine pH.
CNS Additive Effects
Memantine can add to confusion, dizziness or sedation when combined with antipsychotics, benzodiazepines or opioid analgesics.
Alcohol can worsen central nervous system adverse effects such as dizziness and sedation.
E‑Medikation Alerts And Pharmacy Action
Austrian e‑prescription systems typically flag memantine interactions.
Pharmacists should counsel on additive CNS risk and review any urine‑pH altering agents on the medication list.
| Interaction Type | Examples | Advice |
|---|---|---|
| Urine pH Effect | Sodium bicarbonate, carbonic anhydrase inhibitors | Monitor levels and renal clearance; consider dose adjustment |
| CNS Depression/Additive Confusion | Antipsychotics, benzodiazepines, opioids, alcohol | Warn caregiver/patient; review need for combination |
Cultural Features And Patient Behaviour In Austria
How Do Austrian Patients Access And Use Memantine?
Prescriptions commonly follow specialist assessment, and families or caregivers usually manage adherence and monitoring.
Urban centres such as Wien, Graz and Linz have easier access to specialists and a higher pharmacy density.
Rural regions rely on independent Apotheken with postal or delivery services to maintain continuity of supply.
Cross‑Border Shopping
Cross‑border purchases into Germany, Czech Republic or Hungary occur for price or availability reasons in border regions, though reimbursement through Sozialversicherung generally requires an Austrian prescription.
Role Of Pharmacies
Independent Apotheken remain highly trusted for counselling, while national chains and online pharmacies are increasing their footprint and services.
Online Ordering Note
In our online pharmacy, namenda is available without a prescription, with discreet delivery to Australia in 5-14 days.
Care And Stigma
Stigma around dementia can delay help‑seeking and multi‑generational households often play a central role in day‑to‑day medication management.
Availability And Price Overview
Where To Get Memantine In Austria
Memantine is prescription‑only in Austria and reimbursed by Sozialversicherung for labelled indications when prescribed appropriately.
Price regulation and reference pricing limit out‑of‑pocket costs for patients, and generics such as Memantin Genericon are commonly stocked alongside Ebixa.
Dispensing Workflow
Prescribers issue an e‑card prescription which pharmacists validate via E‑Medikation and maintain records for reimbursement.
Common Pack Sizes And Outlets
Tablets commonly come in blister packs of 28–98 units and oral solution in 30–50 mL bottles with a dosing syringe.
Availability tends to be broad across independent Apotheken, chains like BENU and some pharmacy counters in retail chains.
| Aspect | Details |
|---|---|
| Reimbursement | Reimbursed under Sozialversicherung for licensed indications |
| Common Pack Sizes | Tablets: 28/30/56/98; Oral solution: 30–50 mL |
| Where To Buy | Independent Apotheken, BENU, accredited online pharmacies (e‑prescription required) |
Comparable Medicines And Preferences
What Are The Alternatives To Memantine?
Acetylcholinesterase inhibitors are the principal alternatives and include donepezil, rivastigmine and galantamine.
Memantine Is Typically Chosen For Moderate–Severe Disease
Memantine is usually selected when patients reach moderate–severe Alzheimer’s disease or when AChE inhibitors are insufficient or not tolerated.
Combination Therapy
Combination of memantine with an AChE inhibitor is common in Austria and aims to target complementary pathways for symptomatic benefit.
Pros And Cons At A Glance
| Drug | Mechanism | Typical Stage | Pros | Cons |
|---|---|---|---|---|
| Memantine | NMDA receptor antagonist | Moderate–Severe AD | Well tolerated; benefit in ADL; twice‑daily dosing | Modest cognitive gains; limited effect in mild AD |
| Donepezil / Rivastigmine / Galantamine | AChE inhibitors | Mild–Moderate AD | Better evidence in mild–moderate stages for cognition | Gastrointestinal side effects; dosing complexity for some formulations |
Frequently Asked Questions
How And When Should My Relative Take Memantine?
Begin with 5 mg once daily and increase weekly by 5 mg to reach 10 mg twice daily (20 mg/day) as the usual maintenance regimen.
Oral solution (10 mg/mL) is available and the supplied syringe should be demonstrated for accurate dosing if swallowing is difficult.
Will Memantine Stop Alzheimer’s Progression?
Memantine is symptomatic and can slow functional decline in moderate–severe disease but is not a disease‑modifying treatment.
Expect modest benefits and schedule regular clinical review to assess ongoing suitability.
Is It Reimbursed And Where Can I Get It?
Memantine is prescription‑only and reimbursed by Sozialversicherung for its licensed indication in Austria, and it can be dispensed in any accredited pharmacy with an e‑card prescription.
What Are The Common Side Effects And Driving Advice?
Dizziness, constipation and confusion are common side effects and patients should avoid driving or hazardous tasks until stability is ensured.
Guidelines For Correct Use
What Should Pharmacists Cover In Counselling?
Confirm the indication and ensure the e‑prescription is in place before dispensing.
Explain the titration schedule clearly and emphasise not to double doses if one is missed.
Demonstrate the dosing syringe for oral solution and provide written instructions for caregivers where appropriate.
Warn about dizziness and advise simple fall precautions such as using a walking aid and ensuring good lighting at home.
Storage And Interprofessional Communication
Store tablets at room temperature and protect the oral solution from light.
Document memantine on the patient’s E‑Medikation record to alert other clinicians and pharmacists to interaction risks.
When To Refer Urgently
Seek prescriber or emergency care for severe confusion, new‑onset seizures, severe allergic reactions or recurrent falls after starting memantine.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Geelong | Victoria | 5-7 days |
| Townsville | Queensland | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Alice Springs | Northern Territory | 5-9 days |
Final Notes For Pharmacists And Prescribers
Keep The Caregiver In The Loop.
Involve family or carers in counselling, provide written instructions and schedule follow‑up to assess functional response and tolerability.
Document Memantine Clearly On E‑Medikation.
That ensures interaction checks and continuity of care across prescribers and pharmacies.
When In Doubt, Review Renal Function.
Older patients should have renal function checked periodically and doses adjusted for severe impairment according to guidance.
Supply And Reimbursement.
Memantine is prescription‑only and generally reimbursed for licensed indications in Austria, and both originator and generic brands are commonly available.
